Teladoc Health, Inc. TDOC
6.09
(0.05)
(0.81%)
as of 25 Sep
- Market cap
- $1.1B
- P/E
- 0.0×
Follow TDOC
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.62 | 0.39 | 0.49 | 0.54 | |
P/FCF ratio |
17.33 | 7.71 | 8.98 | 12.63 | |
P/Operating CF |
23.74 | 102.59 | 14.06 | 13.78 | |
P/B ratio |
1.17 | 0.73 | 0.89 | 0.98 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.11 | 0.70 | 0.79 | 0.86 | |
EV/EBITDA |
13.51 | 9.38 | 10.79 | 13.21 | |
EV/Operating CF |
10.54 | 6.15 | 6.79 | 7.47 | |
EV/FCF |
31.09 | 13.99 | 14.55 | 20.18 | |
Quick Ratio |
0.72 | 2.38 | 2.41 | 2.31 | |
Current Ratio |
0.83 | 2.80 | 2.77 | 2.70 | |
Net Debt/EBITDA |
4.02 | 7.56 | 3.38 | 5.07 | |
Debt/Assets |
36.13% | 35.47% | 34.81% | 34.53% | |
Debt/Equity |
0.76 | 0.75 | 0.72 | 0.71 | |
Asset Turnover |
0.88 | 0.80 | 0.79 | 0.79 | |
Operating CF/Net income |
(1.66) | (0.15) | (3.49) | (2.00) | |
Capex/Depreciation |
(0.45) | (0.38) | (0.35) | (0.30) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
10.36% | 11.06% | 11.15% | 10.79% | |
Selling, General and Administrative Expense of Revenue |
48.90% | 49.67% | 47.60% | 50.89% | |
Intangible Assets out of Total Assets |
0.53 | 0.54 | 0.55 | 0.56 | |
Share Based Compensation of Revenue |
1.53% | 2.38% | 2.48% | 2.71% | |
Graham Net Nets |
(0.20) | (0.35) | (0.29) | (0.29) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(11.67%) | (17.80%) | (16.29%) | (16.56%) | |
Free Cash Flow Yield |
5.77% | 12.98% | 11.13% | 7.92% | |
Revenue per Share |
3.35 | 3.43 | 3.64 | 3.54 | |
Operating CF per Share |
0.36 | 0.05 | 0.50 | 0.56 | |
Capex per Share |
(0.23) | (0.20) | (0.19) | (0.18) | |
Free Cash Flow per Share |
0.13 | (0.15) | 0.30 | 0.38 | |
Cash per Share |
4.28 | 4.19 | 4.43 | 4.10 | |
Shareholders Equity per Share |
7.24 | 7.46 | 7.86 | 7.87 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.24 | 7.46 | 7.86 | 7.87 | |
Free Cash Flow |
23.07 | (26.31) | 53.42 | 67.95 | |
Working Capital |
(233.37) | 727.47 | 714.39 | 687.67 | |
Capital Expenditures |
(41.59) | (35.82) | (34.32) | (31.32) | |
Net Current Asset Value |
(300.16) | (338.61) | (353.46) | (393.67) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.07 | 0.06 | 0.05 | 0.05 | |
Net Profit Margin |
(6.41%) | (10.40%) | (3.91%) | (7.90%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
223.22 | 223.30 | 203.49 | 211.40 | |
Average Payables |
45.97 | 48.63 | 40.55 | 45.00 | |
Average Inventory |
33.49 | 34.78 | 38.17 | 38.45 | |
Average Assets |
2,826.31 | 3,125.85 | 3,187.41 | 3,203.56 | |
Average Common Equity |
1,366.12 | 1,381.67 | 1,438.39 | 1,449.91 |
Columns are period end dates